

FOI Request re Urothelial Cancer Patients

Please indicate the number of metastatic or locally advanced Urothelial¹ cancer patients treated² by your Trust in the 3 months, **July 2018 to September 2018** inclusive.

If data is not held in a sufficient way within your Trust systems, i.e. if for example you are unable to distinguish between cancer type and/or stage, please indicate accordingly within the tables below.

	Total number treated (Metastatic/locally advanced Urothelial patients)	If unable to provide number of metastatic/locally advanced Urothelial patients, please indicate the level at which data has been provided:	
Total number of metastatic or locally advanced Urothelial cancer (UCC, transitional carcinoma, TCC) patients treated	57	Total Urothelial Cancer patients (any stage)	
		Other (please specify)	
		Data not held/accessible	

Of the metastatic or locally advanced Urothelial cancer patients treated by your Trust in the 3 months, **July 2018 to September 2018** inclusive, please indicate the number treated with the following therapies.

Therapy	Total number treated (Metastatic/locally advanced Urothelial patients)	If unable to provide number of metastatic/locally advanced Urothelial patients, please indicate the level at which data has been provided:	
Cisplatin (mono or combination therapy)	Please note that Cisplatin and carboplatin patients may include 'adjuvant' or patients at a lower stage, To provide treatment numbers for only metastatic/locally advanced would require detailed analysis of all patients notes which would be exempt under section 12 of the FOI Act, therefore we have provided the above figures under Section 16 of the FOI Act.	Total Urothelial Cancer patients (any stage)	10
		Other (please specify)	
		Data not held/accessible	
Carboplatin (mono or combination therapy)	Please note that Cisplatin and carboplatin patients may include 'adjuvant' or patients at a lower stage, To provide treatment numbers for	Total Urothelial Cancer patients (any stage)	7
		Other (please specify)	
		Data not held/accessible	

¹ ICD10 C65, C66, C67, C68; TNM staging for metastatic Urothelial Cancer = Any T, any N, M1; TNM staging for locally advanced Urothelial Cancer = Any T, N2-3, M0 or T4b, any N, M0; Please include numbers for:

- any diagnosis of metastatic disease as opposed to patients that present with metastases
- all metastatic sites from a Urothelial primary

² Please indicate the number of patients (excluding clinical trial patients) treated with any active anti-cancer drug treatment.

	only metastatic/locally advanced would require detailed analysis of all patients notes which would be exempt under section 12 of the FOI Act, therefore we have provided the above figures under Section 16 of the FOI Act.		
Pembrolizumab (Keytruda)	10	Total Urothelial Cancer patients (any stage)	
		Other (please specify)	
		Data not held/accessible	
Atezolizumab (Tecentriq)	Less than 5- section 40 exemption	Total Urothelial Cancer patients (any stage)	
		Other (please specify)	
		Data not held/accessible	

If your trust does not treat these cancers and you refer your patients to another trust, please state to which trust(s) patients are referred:

FOI Ref 398-1819